Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1215 details
Primary information
ThPP IDTh1029
Therapeutic Peptide/Protein NameMenotropins
SequenceAlpha-Chain(LH): APDVQDCPECTLQENPFFSQPGAPILQCMGCCF view full sequnce in fasta
Functional ClassificationIb
Molecular Weight23390.3
Chemical FormulaC1014H1609N287O294S27
Isoelectric Point8.44
Hydrophobicity-0.063
Melting Point (℃)55
Half LifeN.A.
DescriptionMenotropins contains follicle stimulating hormone and luteinizing hormone purified from the urine of postmenopausal women. It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunit alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.
Indication/DiseaseFor the treatment of female infertility
PharmacodynamicsMenotropins is used to treat female infertility, stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Menotropins bind to the LH/hCG/FSH receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.
Mechanism of ActionMenotropins is a combination drug which binds to the Follicle stimulating hormone receptor (which results in ovulation in the absence of sufficient endogenous Luteinizing hormone)and it also binds to the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH,therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure.FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesFertility Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionAntagon (ganirelix)
TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor
Information of corresponding available drug in the market
Brand NameMenopur
CompanyN.A.
Brand DiscriptionMENOPUR is a preparation of gonadotropins (FSH and LH activity), extracted from the urine of postmenopausal women, which has undergone additional steps for purification
Prescribed forMenotropins are used to stimulate ovulation (the release of an egg) when a woman's ovaries can produce a follicle but hormonal stimulation is deficient. Menotropins are also used to stimulate the development of multiple eggs for in vitro fertilization. Li
Chemical NameN.A.
FormulationEach vial of MENOPUR contains 75 International Units of follicle-stimulating hormone (FSH) activity and 75 International Units of luteinizing hormone (LH) activity, plus 21 mg lactose monohydrate and 0.005 mg Polysorbate 20 and Sodium Phosphate Buffer (So
Physcial AppearnceSterile, lyophilized powder which is reconstitution with Sterile 0.9% Sodium Chloride Injection.
Route of AdministrationSubcutaneous Injection
Recommended DosageThe dosing scheme for patients undergoing IVF follows a stepwise approach and is individualized for each woman. The recommended initial dose of MENOPUR for women who have received a GnRH agonist for pituitary suppression is 225 International Units. MENOPU
ContraindicationHypersensitivity, high level of FSH indicating primary ovarian failure, cause fetal harm when administerd to prergnant woman, ex hormone dependent tumors of the reproductive tract and accessory organs.
Side EffectsLess than 2% of female patients treated with menotropins develop ovarian hyperstimulation syndrome (OHSS), especially after the first cycle of therapy. Symptoms of OHSS include swelling of the hands or legs, abdominal pain and swelling, shortness of breathing.
Useful Linkhttp://www.drugs.com/drug-interactions/menotropins,menopur-index.html
PubMed ID18020563
3-D StructureTh1029 (View) or (Download)